HR011408 (rapid-acting insulin biosimilar)
/ Jiangsu Hengrui Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 21, 2024
Comparison of HR011408 and NovoRapid® in Subjects With Diabetics
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Diabetes • Metabolic Disorders
April 19, 2024
Comparison of HR011408 and NovoRapid® in Subjects With Diabetics
(clinicaltrials.gov)
- P1 | N=30 | Not yet recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd.
New P1 trial • Diabetes • Metabolic Disorders
February 07, 2024
The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject
(clinicaltrials.gov)
- P1 | N=61 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Recruiting ➔ Completed
Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
April 12, 2023
The Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Healthy Subject
(clinicaltrials.gov)
- P1 | N=44 | Recruiting | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Diabetes • Metabolic Disorders
1 to 4
Of
4
Go to page
1